Clinical trial data were used to evaluate cancer outcomes between older (n [ 251) and younger (n [ 704) patients with metastatic colorectal cancer who were treated with cetuximab. Overall survival trended toward favoring younger adults, but in general, outcomes, including quality-of-life benefit, were similar between age groups. Background: The safety and efficacy of targeted therapy in older patients ( 70 years) with metastatic colorectal cancer is not well evaluated. Patients and Methods: Outcomes of older patients (including overall survival [OS], progression-free survival [PFS], toxicity, and quality of life [QoL]) were compared to young patients using data from 2 large previously reported clinical trials, CO.17 (cetuximab vs. best supportive care) and CO.20 (cetuximab plus placebo vs. cetuximab plus brivanib). Only patients with wild-type KRAS tumors were included. Results: A total of 251 (26.3%) of 955 patients were 70 years old. No significant differences in OS, PFS, or grade 3/4 adverse events were observed between older and younger patients treated with cetuximab (or cetuximab with placebo) in either trial. Younger patients trended toward superior OS in both CO.17 (hazard ratio ¼ 1.80; P ¼ .16) and CO.20 (hazard ratio ¼ 1.34; P ¼ .07). QoL maintenance favored younger patients in CO.17 (3.6 vs. 5.7 months; P ¼ .046) but no difference of QoL maintenance was observed in the larger CO.20 trial (1.7 vs. 1.8 months; P ¼ .64). Combination therapy of cetuximab and brivanib was significantly more toxic in older adults (87% vs. 77%; P ¼ .03). Conclusion: OS, PFS, and toxicities were similar between older and younger patients with wild-type KRAS metastatic colorectal cancer when treated with cetuximab. Both age groups likely experience similar QoL maintenance with cetuximab. Dual targeted therapy was significantly more toxic in older patients.
Introduction
Colorectal cancer (CRC) is the third most prevalent type of cancer in North America and is the second leading cause of cancerrelated death. 1 The median age of diagnosis in the United States and other developed nations is 70 years old. 2 The optimal treatment of older CRC patients is not well defined, as older patients have been underrepresented in clinical trials, resulting in a lapse of high-quality evidence. [3] [4] [5] This patient population is unique in that treatment decisions are significantly influenced by comorbidities, risk aversion to treatment-related toxicities, and focus on maintenance of quality of life (QoL). 6, 7 The past decade has experienced a large expansion in the number of treatment options for metastatic CRC. Various combinations of chemotherapy, including fluropyrimidines, irinotecan, and oxaliplatin, have improved overall survival (OS) in CRC patients, and these combinations appear to have similar benefits and toxicities in both young and fit older patients. 3, [8] [9] [10] Numerous novel targeted therapies, including bevacizumab, cetuximab, panitumumab, aflibercept, ramucirumab, and regorafenib, have shown efficacy in CRC. Their use in older patients, as single agents or in combination with chemotherapy, is less well documented. The exception to this is bevacizumab, in which several elderly-specific trials have been performed and are suggestive of efficacy and safety. 11, 12 Cetuximab is a monoclonal antibody that inhibits the epithelial growth factor receptor (EGFR), resulting in inhibition of cell growth and apoptosis. 13 Cetuximab significantly increases the OS and progression-free survival (PFS) in metastatic CRC patients with wild-type RAS tumors. [14] [15] [16] No immediate toxicity concerns have been identified in several previous studies evaluating older patients treated with cetuximab with or without chemotherapy. [17] [18] [19] [20] [21] Fewer studies exist demonstrating the efficacy of cetuximab as a second-line or later agent in the elderly, and no studies have evaluated QoL in elderly patients treated with cetuximab. 14, 21 This study was designed to compare the efficacy, safety, and QoL of older (70þ years) versus younger patients with chemorefractory metastatic CRC receiving targeted therapy using data from 2 previously reported clinical trials.
Patients and Methods

Clinical Trials and Patient Populations
This study analyzed CO.17 and CO.20, two previously reported phase 3 randomized controlled clinical trails conducted by the Canadian Cancer Trials Group and the Australasian GastroIntestinal Trials Group (NCT00079066 and NCT00640471, respectively). 14, 22 In the CO.17 trial, 572 patients were randomized to receive either best supportive care (BSC) or BSC with cetuximab. Cetuximab demonstrated superior OS, PFS, and longer preserved QoL compared to BSC. 14 Subsequent studies found this benefit was limited to patients with wild-type RAS tumors. [14] [15] [16] CO.20 randomized 750 patients to cetuximab plus placebo or to cetuximab plus brivanib alaninate, a dual inhibitor of vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR). The CO.20 trial demonstrated that adding brivanib to cetuximab resulted in improved PFS but no difference in OS and an earlier deterioration in QoL. 22 Eligibility criteria were similar between trials and included the presence of advanced colorectal cancer; no response to or unable to tolerate treatment with fluoropyrimidine, irinotecan, and oxaliplatin therapy; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2; and adequate bone marrow, renal, and hepatic function.
In this study, only patients with wild-type KRAS tumors were included; patient inclusion/exclusions for CO.17/CO.20 are demonstrated in CONSORT-like diagrams in Figures 1 and 2 , respectively. Older patients were defined as those 70 years, consistent with the International Society of Geriatric Oncology, which states, "70 years is currently the most commonly used cut-off for defining patients as elderly." 
Outcome Measures
OS and PFS were measured from time of randomization. Severe toxicity was measured using the incidence of grade 2 and grade 3/4 adverse events using the National Cancer Institute Common Toxicity Criteria version 2.0 (for CO.17) and 3.0 (for CO.20). QoL was measured the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) in each trial. All outcome measures are calculated and reported with similar methodology as the original CO.17 and CO.20 trials. 14, 22 Statistical Analysis OS and PFS were compared between age groups using multivariate Cox models adjusting for potential prognostic factors included in the primary analyses of the trials. Specifically, the following baseline covariates were included in multivariate Cox models for CO. 17 
Results
Patient Characteristics
A total of 955 patients were included in the analysis of this study, of whom 251 (26.3%) were 70 years or older at the time of enrollment. In CO.17, 58 (25.3%) of 230 were aged 70 or older, while in CO.20, 193 (26.6%) of 725 patients were over the age of 70. Baseline characteristics of patients in each trial are listed in Table 1 . In CO.17, baseline serum creatinine, presence of comorbidities, and treatment arm were associated with age in univariate and multivariate analysis, while in CO.20, only liver metastases and presence of comorbidities were associated with age in both univariate and multivariate analyses.
OS and PFS
OS and PFS were statistically similar between older and younger patients treated with cetuximab in both CO.17 and CO.20 In CO.17, only younger patients treated with cetuximab had a significant improvement in both OS and PFS compared to those receiving BSC (OS ¼ 9.7 vs. 4.8 months, P ¼ .0006; and PFS ¼ 3.8 vs. 1.8 months, P < .0001, for cetuximab vs. BSC respectively) ( Table 3 ). The OS and PFS did not reach statistical significance for older patients treated with cetuximab versus those receiving BSC (Table 3) .
Finally, in CO.20, both older and younger patients treated with cetuximab and brivanib had statistically similar OS (7.6 vs. 9.1 months, respectively; P ¼ .62) and PFS (3.7 vs. 5.3 months, respectively; P ¼ .16) ( Table 4 ).
Toxicity and Quality of Life
Grade 3/4 adverse event rates are listed for CO.17 and CO.20 in Tables 5 and 6 , respectively. Older and younger patients receiving cetuximab experienced similar rates of grade 3/4 adverse event rates in both CO.17 (81% vs. 78%; P ¼ .71) and CO.20 (63% vs. 52%; P ¼ .09) ( Table 2 ). In CO.20, older patients treated with cetuximab experienced higher incidences of grade 3/4 abdominal pain (11% vs. 4%; P ¼ .01), dehydration (4% vs. 1%; P ¼ .04), and confusion (3% vs. 0%; P ¼ .01) than younger patients (Table 6 ). Rates of grade 3/4 adverse events were higher in patients treated with cetuximab compared to those receiving BSC, but this was only significant in younger patients (Table 3) .
Grade 2 adverse events for CO.17 and CO.20 are listed in Supplemental Tables 1 and 2 in the online version, respectively. All patients treated with cetuximab in CO.17 experienced grade 2 adverse events, although grade 2 events were frequent in the BSC arm (93% in younger patients, 81% in older patients). Similarly, 95% of older and younger patients in CO.20 experienced grade 2 adverse events when treated with cetuximab and placebo. There were no significant differences between age groups for specific symptoms. The combination of cetuximab and brivanib was significantly more toxic in older patients (87%) than younger patients (77%; P ¼ .03) ( Tables 4 and 6 ). Grade 3/4 fatigue was the most common adverse effect more often seen in older patients (38% vs. 22%; P ¼ .002; Table 6 ).
In patients treated with cetuximab (or cetuximab with placebo), QoL outcomes varied by trial. In CO.17, older patients treated with cetuximab had a less robust benefit to QoL compared to younger patients (3.6 vs. 5.7 months; P ¼ .046), whereas in the larger CO.20 trial, QoL maintenance was similar between older and young (1.8 vs. 1.6 months; P ¼ .64, respectively) ( Table 2) .
When comparing cetuximab to BSC, neither older nor young patients had a statistically significant improvement in QoL with cetuximab treatment (Table 3 ). In CO.20, the combination of cetuximab and brivanib resulted in a maintenance of QoL of 0.9 months for older patients versus 1.2 months for younger patients (P ¼ .02) ( Table 4) .
Discussion
This study was designed to evaluate the outcomes of older patients with KRAS wild-type metastatic CRC undergoing targeted therapy. Our reanalysis of CO.17 and CO.20 suggest that both older and younger patients treated with cetuximab have statistically similar OS, PFS, and QoL maintenance while experiencing similar rates of serious adverse events. However, this unplanned subanalysis (and therefore underpowered) does trend toward improved OS for younger patients in both CO.17 (HR ¼ 1.80; P ¼ .16) and CO.20 (HR ¼ 1.34; P ¼ .07).
Several previous studies examining the outcomes of older patients treated with cetuximab have concluded there are no differences in outcomes between young and older patients. The original CO.17 trial included a planned subanalysis of patients < 65 and 65 years old, from which no differences were observed for OS, PFS, or overall response rates.
14 A subsequent analysis found no relationship between age (using a cutoff of < 65), comorbidities (measured by Charlson comorbidity index), and OS. 19 In heavily pretreated patients, an observational study of 305 older patients ( 65 years old) saw no difference in adverse events or PFS compared to younger patients. 20 A pooled analysis of the OPUS and CRYSTAL trials concluded that first-line cetuximab with chemotherapy was equally effective and had similar toxicities for older ( 70) and younger patients. 17 The primary difference between our analysis and previous analyses of CO.17 is the higher age cutoff of 70, as this age is more consistent with current trends in geriatric oncology, and the complete exclusion of patients with mutant KRAS. This study also differs from other reports in that it uses phase 3 clinical trial data, includes only KRAS wild-type patients, and reports on all of OS, PFS, toxicity, and QoL. Additionally, the majority of other studies thus far have examined cetuximab in combination with chemotherapy. These differences may explain why our analysis showed a strong trend toward younger patients having more prolonged OS. While OS and PFS outcomes are important, treatment toxicity and QoL maintenance are often more heavily weighted in treatment decisions for older patients. 25 To date, this is the first analysis to compare QoL outcomes between older and younger patients treated with cetuximab. Maintenance of QoL was significantly shorter in older patients than younger patients in the CO.17 trial; however, in the larger CO.20 trial, the maintenance of QoL was similar between age groups. The reason for this discrepancy is not clear, as both trials followed similar protocols with the same QoL survey. This may be due to a type II error, as the older CO.17 QoL data included 17 patients whereas the CO.20 data included 84 patients. Toxicity results from CO.17 intuitively demonstrate that cetuximab treatment is more toxic than BSC alone, and both trials show that cetuximab-related grade 2 and 3/4 toxicities are similar between age groups. Overall, treatment with cetuximab was associated with a 100% incidence of grade 2 adverse events, but this must be contrasted against the fact that > 80% of patients receiving BSC will also develop grade 2 adverse events. This shows that both treatment and nontreatment will be associated with burdensome symptoms.
Combination treatment with cetuximab and brivanib was significantly more toxic in older patients than younger patients. Various combinations of targeted therapies have been trialed in metastatic CRC, but thus far none has been approved. In the original CO.20 trial, the combination of cetuximab plus brivanib was found to be more toxic than cetuximab with placebo, and combination therapy did not prolong OS. 22 Several phase 1 and phase 2 studies have combined targeted therapies, including VEGF and EGFR inhibitors, with and without cytotoxic agents, and thus far the combinations appear to be reasonably tolerated, with predictable toxicities. [26] [27] [28] [29] Unfortunately, the median age in these trials was < 65 and most patients had an ECOG PS of 0-1, making it difficult to generalize these results. Nonetheless, our data suggest that greater baseline toxicities of these combinations may adversely affect older patients to a greater extent than younger patients. Fifty-six percent of patients diagnosed with CRC are over the age of 65, yet the number of older adults enrolled onto clinical trials remains disproportionately low; this will inevitably further cloud the optimal treatment of this patient group. 30 In this study, only 26.3% of patients were over the age of 70. As an example of 34 This tool includes an evaluation of functional status (activities of daily living, mobility), physical performance, comorbidities, depression, social support, nutritional status, and cognitive status. 35 Development and incorporation into trials will likely allow for more informed decision making when selecting treatments for older patients. This study is limited by the fact that older patients in clinical trials rarely reflect the "true" older population, who may have more comorbidities and worse performance statuses. While our results are not generalizable to frail elderly patients, 20% of older patients in CO.17 had an ECOG PS of 2, and older patients were more likely to have multiple comorbidities. Similarly, in CO.20 the older cohort had significantly more comorbidities, suggesting our older cohort was different from the younger cohort. The calculation of Charlson comorbidity index is limited by the lack of ICD-10 codes; there was also no manner to determine or adjust for the severity of each comorbidity. Unfortunately, our limited sample size prevented a subset analysis by comorbidities or presence of polypharmacy. A sensitivity analysis of age was not feasible given the small number of older patients (age > 75); sample size also limited the usefulness of analyzing age as a continuous variable.
CO.17 and CO.20 were not originally designed to measure geriatric outcomes, and as such no comprehensive geriatric assessments were performed; however, this is the first study to report QoL outcomes in older patients treated with cetuximab. Other limitations include the retrospective nature of this study, which was conducted using data from well-designed clinical trials, and only controlling for wild-type KRAS rather than extended RAS. Finally, it is important to recognize that age alone should not be used to dictate treatment, and that physiological age may vastly differ from chronological age.
Conclusion
Age was not associated with statistically superior OS or PFS in patients with chemorefractory, KRAS wild-type metastatic CRC treated with cetuximab. However, a strong trend toward improved OS for younger patients treated with cetuximab was observed in both trials. Older patients likely experience similar QoL maintenance and similar toxicity rates compared to younger patients; however, adverse event rates are high. The decision to initiate targeted therapy in older patients should balance modest improvements in cancer-specific outcomes with the high incidence of toxicity. Dual targeted therapy with cetuximab and brivanib was significantly more toxic in the older population. Further recruitment of older patients into clinical trials and elder-specific trials are necessary to better guide treatment decisions in this population.
Clinical Practice Points
Many treatment options are available for chemorefractory metastatic CRC; however, most have been studied in younger clinical trial populations. We demonstrate that older, more comorbid patients (albeit clinical trial patients) benefit from treatment with cetuximab, but predictably experience more side effects than patients not receiving treatment. (27) .70 44 (16) 17 (19) .63
Data are presented as n (%) unless otherwise indicated.
